Prenatal diethylstilbestrol exposure: Transgenerational transmission of adverse effects (notice n° 1920550)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02035cam a2200181 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260329022515.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Epelboin, Sylvie |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Prenatal diethylstilbestrol exposure: Transgenerational transmission of adverse effects |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 19 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Several million women were treated and their fetuses exposed to diethylstilbestrol from the early 1940s to the end of the 1970s, when we did not have medical knowledge of the long-term consequences of fetal exposure to various therapies, or underestimated these consequences. The adverse effects of exposure to diethylstilbestrol on prenatally exposed women and men are widely documented, dominated by adverse pregnancy outcomes in women, and the increased risk of cancer in exposed children of both sexes. There is no longer any doubt that diethylstilbestrol acts as an endocrine disruptor with consequences for the offspring of those exposed, including the grandchildren of women who were prescribed diethylstilbestrol during their pregnancy. Several links in the chain that could have stopped prescription failed, in defiance of the precautionary principle. The history of diethylstilbestrol must therefore be taught in various ways. It serves as a model for thinking about the trend in the medical world to have great enthusiasm for a product or a new technology, but for which, because of the means we now have at our disposal, we absolutely must ensure both efficacy and safety. Faced with the continuing and undeniable progress in the field of reproductive medicine, we must remain vigilant, in particular when it comes to all hormonal therapy prescribed in the early stages of fetal development. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tournaire, Michel |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Devouche, Emmanuel |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Médecine de la Reproduction | 24 | 1 | 2022-01-01 | p. 37-48 | 2650-8427 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/journal-medecine-de-la-reproduction-2022-1-page-37?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-medecine-de-la-reproduction-2022-1-page-37?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux